KeViRx

Manufacturing · Virginia, United States · 1-10 Employees

View Company Info for Free

Overview

Headquarters

722 Preston Ave Ste 108, Charlottesville...

Revenue

<$5 Million

Industry

Manufacturing Pharmaceuticals Business Services Research & Development
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1

About KeViRx

KeViRx, Inc. is a preclinical stage pharmaceutical company headquartered in Charlottesville, VA. The company is developing small molecules drugs that treat microvascular leakage and inflammation, pathologies that are the basis for many diseases, including cancer and respiratory disease. The company is now entering IND-enabling studies for pulmonary microvascular leakage and inflammation during acute lung injury. The company's lead asset, KVX-053 has potent anti-inflammatory and immunomodulatory effects. In preclinical models, KVX-053 reduces lung injury scoring & the biomarkers of lung injury, inflammation & proinflammatory cytokine release, & immune cell infiltration into the lung. KVX-053 also improves lung function after lung injury. Contact the company for more information at info@KeViRx.com.Explore more
KeViRx's Social MediaPopular SearchesKeViRxKevirx IncSIC Code 28,283NAICS Code 32,325Show more

KeViRx Org Chart

ES
United States flag for contact location.

Chief Executive Officer & Co-Founder

PhoneEmail
JL
United States flag for contact location.

Chief Scientific Officer

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.

Is KeViRx your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Compare Similar Companies to KeViRx

Compare insights from companies similar to KeViRx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

KeViRx

<$5M
1-10
Private
-
2016
ES
Elizabeth SharlowCEO & Co-Founder
$11.1M
11-50
Private
<$5M
2005
Patty Ferrante, Chief Operating Officer at Melior Discovery
Patty FerranteChief Operating Officer
<$5M
11-50
Private
-
1998
N/A
<$5M
1-10
Private
-
-
N/A
<$5M
11-50
Private
-
2007
N/A
<$5M
1-10
Private
-
2011
NL
Najib LamharziPresident & CEO & Founder
11-50
Public
$199.6M
1996
James Caruso, President, Chief Executive Officer & Director at Cellectar Biosciences
James CarusoPresident, CEO & Director
Illustration of an envelope

Company Profile Activity

i

Among all Manufacturing companies

Low Activity

High Activity

Activity Insights

KeViRx is experiencing very low activity levels compared to other companies in the Manufacturing sector.

What does this means?

KeViRx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about KeViRx.

KeViRx Tech Stack

A closer look at the technologies used by KeViRx

KeViRx News & Media

Read more news

Top Manufacturing Companies

Frequently Asked Questions Regarding KeViRx

What is KeViRx's official website?
KeViRx's official website is www.kevirx.com
What is KeViRx's Revenue?
KeViRx's revenue is <$5 Million
What is KeViRx's SIC code?
KeViRx's SIC: 28,283
What is KeViRx's NAICS code?
KeViRx's NAICS: 32,325
How many employees does KeViRx have?
KeViRx has 1-10 employees
What industry does KeViRx belong to?
KeViRx is in the industry of: Manufacturing, Pharmaceuticals, Business Services
What is KeViRx competition?
KeViRx top competitors include: Oncotherapy Solutions, Frost Biologic, Prothix, Cellectar Biosciences
What technology does KeViRx use?
Some of the popular technologies that KeViRx uses are: Hostgator, Hostgator Email
What does KeViRx do?

KeViRx, Inc. is a preclinical stage pharmaceutical company headquartered in Charlottesville, VA. The company is developing small molecules drugs that treat microvascular leakage and inflammation, pathologies that are the basis for many diseases, including cancer and respiratory disease. The company is now entering IND-enabling studies for pulmonary... microvascular leakage and inflammation during acute lung injury. The company's lead asset, KVX-053 has potent anti-inflammatory and immunomodulatory effects. In preclinical models, KVX-053 reduces lung injury scoring & the biomarkers of lung injury, inflammation & proinflammatory cytokine release, & immune cell infiltration into the lung. KVX-053 also improves lung function after lung injury. Contact the company for more information at info@KeViRx.com.Read More

What are KeViRx social media links?
KeViRx Linkedin page
Is KeViRx a public company?
KeViRx is private company therefore does not currently have an official ticker symbol
See more information about KeViRx

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.